Kura Oncology (KURA) Share-based Compensation (2014 - 2026)

Kura Oncology (KURA) has 13 years of Share-based Compensation data on file, last reported at $69000.0 in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 99.12% year-over-year to $69000.0 in Q1 2026; TTM through Mar 2026 was $19.8 million, a 28.95% decrease from a year earlier, with the FY2025 full-year figure at $37.1 million, down 15.66% from the prior year.
• Share-based Compensation for Q1 2026 stood at $69000.0, down from $11.4 million in the prior quarter.
• Over the last five years, Share-based Compensation for KURA reached as high as $41.0 million in Q3 2025 and fell as low as -$15.1 million in Q4 2022.
• Historically, Share-based Compensation has averaged $5.4 million across 5 years, with a median of $3.0 million in 2024.
• Across the five-year window, Share-based Compensation slumped 335.95% in 2022 and surged 9809.52% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at -$15.1 million in 2022, then soared by 147.48% to $7.2 million in 2023, then grew by 20.43% to $8.6 million in 2024, then surged by 31.53% to $11.4 million in 2025, then sank by 99.39% to $69000.0 in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $69000.0 in Q1 2026, $11.4 million in Q4 2025, and $41.0 million in Q3 2025.